MRSA Breakthrough Announced for the AsepticSure(TM) Hospital Sterilization System
SAN FRANCISCO, Nov. 10 Medizone International, Inc. (OTC Bulletin Board: MZEI) announces that following several months of research, AsepticSure(TM) can now achieve a level of bacterial decontamination heretofore unseen in open space settings using conventional means. Dr Michael E. Shannon, Director of Medical Affairs, Medizone International stated, "Our research team has pressed hard over the last few months to systematically evaluate various decontamination options involving numerous technological approaches in combination, and to our surprise, we have managed reliably and predictably to break through the 6 log barrier with MRSA. This unexpected development will significantly expand the utility for AsepticSure(TM), since by definition, any bacterial reduction beyond 6 logs (99.9999%) is considered STERILIZATION. This unique combination of technologies and protocols will now be tested on C difficile, E coli, Pseudomonas aeruginous, and VRE with the expectation that AsepticSure(TM) will achieve the same degree of incremental improvement over the 4 to 5 log reductions we have already demonstrated with those pathogens in earlier trials."
Medizone International is preparing a second patent filing to cover these developments while construction and instrumentation of an expanded laboratory setting at the company's Innovation Park, Queens University laboratory continues in preparation for full room scale-up testing of its equipment to commence in December.
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Current trials are now being expanded to include a hospital mock-up to be followed by hospital beta testing. Initial sales are targeted to commence early in 2010.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Investor Relations: 415-868-0300 / web site: www.medizoneint.com E-mail: operations @ medizoneint.com
SOURCE Medizone International, Inc.
You May Also Like